Literature DB >> 34321288

Low grade endometrioid endometrial cancer: complexities beyond p53abn.

Russell R Broaddus1, Katherine C Kurnit2.   

Abstract

Entities:  

Keywords:  endometrial neoplasms; pathology; uterine cancer

Mesh：

Year:  2021        PMID： 34321288      PMCID： PMC8759090          DOI： 10.1136/ijgc-2021-002941

Source DB:  PubMed          Journal:  Int J Gynecol Cancer        ISSN： 1048-891X            Impact factor:   4.661


× No keyword cloud information.
  5 in total

1.  Mismatch repair deficiency identifies patients with high-intermediate-risk (HIR) endometrioid endometrial cancer at the highest risk of recurrence: A prognostic biomarker.

Authors:  Floor J Backes; Jennifer Haag; Casey M Cosgrove; Adrian Suarez; David E Cohn; Paul J Goodfellow
Journal:  Cancer       Date:  2018-12-18       Impact factor: 6.860

2.  Molecular markers in recurrent stage I, grade 1 endometrioid endometrial cancers.

Authors:  Marisa R Moroney; Kurtis D Davies; Adam C Wilberger; Jeanelle Sheeder; Miriam D Post; Amber A Berning; Christine Fisher; Carolyn Lefkowits; Saketh R Guntupalli; Kian Behbakht; Bradley R Corr
Journal:  Gynecol Oncol       Date:  2019-03-22       Impact factor: 5.482

3.  Clinicopathologic and Immunohistochemical Correlates of CTNNB1 Mutated Endometrial Endometrioid Carcinoma.

Authors:  Danielle C Costigan; Fei Dong; Marisa R Nucci; Brooke E Howitt
Journal:  Int J Gynecol Pathol       Date:  2020-03       Impact factor: 2.762

Review 4.  p53abn Endometrial Cancer: understanding the most aggressive endometrial cancers in the era of molecular classification.

Authors:  Amy Jamieson; Emily F Thompson; Jutta Huvila; C Blake Gilks; Jessica N McAlpine
Journal:  Int J Gynecol Cancer       Date:  2021-02-15       Impact factor: 3.437

5.  CTNNB1 (beta-catenin) mutation identifies low grade, early stage endometrial cancer patients at increased risk of recurrence.

Authors:  Katherine C Kurnit; Grace N Kim; Bryan M Fellman; Diana L Urbauer; Gordon B Mills; Wei Zhang; Russell R Broaddus
Journal:  Mod Pathol       Date:  2017-03-10       Impact factor: 7.842
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.